Michelle Gilson
Stock Analyst at Morgan Stanley
(1.11)
# 3,664
Out of 4,940 analysts
31
Total ratings
32.14%
Success rate
-7.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $4.30 | +365.12% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $72.30 | -58.51% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $5.81 | +192.60% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $191.49 | +2.36% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $16.94 | +165.64% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $13.10 | +480.15% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $57.33 | +58.73% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $4.30
Upside: +365.12%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $72.30
Upside: -58.51%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $5.81
Upside: +192.60%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $191.49
Upside: +2.36%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $16.94
Upside: +165.64%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $13.10
Upside: +480.15%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $57.33
Upside: +58.73%